December 19, 2007
Genzyme Arthritis Drug Approved In Europe
By Matthew L. Brown
Cambridge-based Genzyme Corp. said its Synvisc-One drug has been granted approval in Europe as a single-treatment pain management for knee osteoarthritis.
The company said the approval is based on clinical data that shows that three doses of Synvisc taken in a single treatment is safe and effective in providing pain relief for up to six months.
The company said the drug could simplify osteoarthritis knee pain management, provide convenience and reduce the cost of therapy.
The company said the approval is based on clinical data that shows that three doses of Synvisc taken in a single treatment is safe and effective in providing pain relief for up to six months.
The company said the drug could simplify osteoarthritis knee pain management, provide convenience and reduce the cost of therapy.
WBJ Web Partners
Most Recent
Most Recent
0 Comments